As­traZeneca makes case for use of blood thin­ner Bril­in­ta in stroke pa­tients

As­traZeneca’s ex­trav­a­gant pro­jec­tions for its clot fight­er Bril­in­ta may have fiz­zled in the face of un­der­whelm­ing tri­al da­ta — but a new piv­otal study is set to ex­pand its use sub­stan­tial­ly.

On Mon­day, the British drug­mak­er said the drug, when tak­en in con­junc­tion with as­pirin, in­duced a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion in the risk of the pri­ma­ry com­pos­ite end­point of stroke and death, com­pared to as­pirin alone, in 11,000 pa­tients that have suf­fered mi­nor acute is­chemic stroke or a high-risk tran­sient is­chemic at­tack (TIA).

De­tailed da­ta from the tri­al, dubbed THALES, are still to come.

There are about 2.2 mil­lion is­chemic stroke pa­tients in ma­jor mar­kets, which is a sub­stan­tial ex­pan­sion over the cur­rent acute coro­nary syn­drome (ACS) in­di­ca­tion of rough­ly 4.3 mil­lion pa­tients, Jef­feries an­a­lyst Pe­ter Welford wrote in a note, fore­cast­ing $2.5 bil­lion in glob­al peak sales, as­sum­ing patent ex­piry by 2024.

The drug gen­er­at­ed rough­ly $1.15 bil­lion in the first nine months of last year and was As­traZeneca’s third-biggest sell­er.

In 2016, As­traZeneca start­ed edg­ing away from its $3.5 bil­lion peak rev­enue pro­jec­tion for the drug af­ter it failed two big stud­ies, deal­ing a blow to Bril­in­ta’s prospects. In par­tic­u­lar, in the SOCRATES tri­al, Bril­in­ta failed to dif­fer­en­ti­ate it­self from as­pirin in pa­tients with acute is­chemic stroke or tran­sient is­chemic at­tack.

In a sep­a­rate tri­al, the drug proved no bet­ter than as­pirin alone in re­duc­ing the risk of death, stroke or heart at­tack in pa­tients with pe­riph­er­al artery dis­ease. How­ev­er, in 2017 — as part of a sub-group analy­sis — the clot fight­er was shown to in­duce a sub­stan­tial 29% re­duc­tion in the risk of car­dio­vas­cu­lar death in pa­tients who had pre­vi­ous­ly suf­fered a heart at­tack and who con­tin­ued to take the treat­ment as well as as­pirin past the first full year of ther­a­py.

In 2019, THEMIS head­line tri­al re­sults sug­gest­ed that the drug — in con­junc­tion with as­pirin — showed a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion on a com­pos­ite end­point of ma­jor ad­verse car­dio­vas­cu­lar events (CV death, my­ocar­dial in­farc­tion or stroke) in di­a­bet­ics with coro­nary artery dis­ease with no pri­or heart at­tack, my­ocar­dial in­farc­tion, or stroke, com­pared to as­pirin alone.

How­ev­er, de­tailed da­ta on the blood thin­ner from the 19,000-pa­tient tri­al lat­er showed that the ben­e­fit was ac­com­pa­nied by a sig­nif­i­cant­ly high­er risk of ma­jor bleed­ing. In ad­di­tion, the in­ci­dence of in­tracra­nial he­m­or­rhage and fa­tal bleed­ing were al­so high­er in the Bril­in­ta group.

Tal Zaks, Moderna CMO (Moderna via YouTube)

UP­DAT­ED: NI­AID and Mod­er­na spell out a 'ro­bust' im­mune re­sponse in PhI coro­n­avirus vac­cine test — but big ques­tions re­main to be an­swered

The NIAID and Moderna have spelled out positive Phase I safety and efficacy data for their Covid-19 vaccine mRNA-1273 — highlighting the first full, clear sketch of evidence that back-to-back jabs at the dose selected for Phase III routinely produced a swarm of antibodies to the virus that exceeded levels seen in convalescent patients — typically in multiples indicating a protective response.

Moderna execs say plainly that this first stage of research produced exactly the kind of efficacy they hoped to see in humans, with a manageable safety profile.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.

Tillman Gerngross, Adagio Therapeutics CEO

An­ti­body leg­end Till­man Gern­gross is el­bow­ing his way in­to the Covid-19 R&D cru­sade: 'I don’t see this end­ing any­time soon'

One of the most influential — and outspoken — scientists at work in the field of antibody discovery is jumping into the frenzied race to create new therapeutics to treat and prevent Covid-19. And he’s operating with the conviction that the current outbreak now once again spreading like wildfire will create plenty of demand for what he has in mind.

Dartmouth professor and Adimab CEO Tillman Gerngross tells me he’s raised $50 million from a group of close VCs to spin out a new company — Adagio Therapeutics — with a full C-suite team assembled to hire up a staff and keep rolling toward the clinic.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Trans­port Sim­u­la­tion Test­ing for Your Ther­a­py is the Best Way to As­sure FDA Ex­pe­dit­ed Pro­gram Ap­proval

Modality Solutions is an ISO:9001-registered biopharmaceutical cold chain engineering firm with unique transport simulation capabilities that support accelerated regulatory approval for biologics and advanced therapeutic medicinal products (ATMP). Our expertise combines traditional validation engineering approaches with regulatory knowledge into a methodology tailored for the life sciences industry. We provide insight and execution for the challenges faced in your cold chain logistics network.

Norbert Bischofberger, Kronos CEO

Gilead­'s ex-R&D chief Bischof­berg­er heads back to the biotech gi­ant to pick up a pair of late-stage drugs that had been put aside

Norbert Bischofberger knows entospletinib well.

Back during his long, blockbuster run as head of R&D at Gilead, researchers had once held some high hopes for this drug. But to make it work, he and the team felt it would need a new companion diagnostic to identify patients. There was talk of a combo approach to give it more punch. But the market was small, making them wonder if it would be worth going through a lengthy development cycle to get it through a pivotal.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.

The $1B Mer­ck-Bay­er drug that di­vid­ed car­di­ol­o­gists in March gets pri­or­i­ty re­view

Three months after Merck published in the New England Journal of Medicine data that left doctors and investors divided over just how well its experimental heart drug worked, the FDA has handed that drug priority review. A decision is now due by January 20, 2021.

Merck first announced the drug, known as vericiguat, as a Phase III success last November. In 2016, Merck had paid $1 billion upfront for US rights to the Bayer-developed drug. Early projections foresaw a few hundred million a year in sales, but the unspecified late-stage success raised the possibility for far more. After all, Novartis’s flagship heart drug, Entresto, was earning $1.7 billion per year and was expected to reach up to $4 billion in annual sales.

GSK’s Shin­grix leader Guil­laume Pfe­fer has jumped on board Flag­ship to helm a biotech hy­brid as Afeyan’s lat­est CEO-part­ner

After spending 4 years in a senior post with GlaxoSmithKline’s star team positioning Shingrix for a blockbuster approval, Guillaume Pfefer is headed back to the biotech world — in style.

Pfefer has signed on to join Noubar Afeyan’s busy group of partners at Flagship, and he’s taking the helm of an upstart — which today is being merged with another Flagship startup — with some grand plans of its own. The announcement this morning notes that Pfefer will run Kintai Therapeutics, one of the grads of the Flagship labs.

Donald Trump and Anthony Fauci (AP Images)

Covid-19 roundup: Rus­sia hack­ers tar­get US,UK vac­cine and drug re­searchers; Fau­ci fires back at White House cam­paign to un­der­mine him

Russia has tried to steal Covid-19 vaccine and therapeutics researcher from pharmaceutical and academic institutions in the US, UK and Canada, Britain’s National Cyber Security Centre said Thursday.

The NCSC said that hacking attempts came from a group known as APT129, also known as also known as ‘Cozy Bear,’ that “almost certainly operate as part of Russian intelligence services.” The Canadian Communication Security Establishment, US Department for Homeland Security, the Cybersecurity Infrastructure Security Agency, and the National Security Agency shared the assessment, the NCSC said.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.

John Furey, Imvax CEO

A neu­ro­sur­geon spent the past 30 years de­vel­op­ing a neoanti­gen tu­mor vac­cine. Now he has $112M for a piv­otal test

As a neurosurgeon, David Andrews knew there wasn’t much he could do for his glioma patients after resecting — rarely fully — their tumor. Even with the best treatment and care available, median overall survival is just somewhere between 14 and 16 months.

Then in the 1990s, his mentor at Thomas Jefferson University introduced him to Renato Baserga, a pathologist who had been studying the effect of using antisense oligonucleotide to knock out the insulin-like growth factor type 1 receptor in cancers. As IGF-R1 drives tumor growth and metastasis, the preclinical reasoning went, implanting a molecule targeting the receptor together with the tumor material near lymph nodes can slow down the spread of the cancer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.

Source: Shutterstock

Who are the women blaz­ing trails in bio­phar­ma R&D and lead­ing the fight against Covid-19? Nom­i­nate them for End­points' spe­cial re­port

One of the many inequalities the pandemic has laid bare is the gender imbalance in biomedical research. A paper examining Covid-19 research authorship wondered out loud: Where are the women?

It’s a question that echoes beyond our current times. In the biopharma world, not only are women under-represented in R&D roles (particularly at higher levels), their achievements and talents could also be undermined by stereotypes and norms of leadership styles. The problem is even more dire for women of color.